

PROF.DR. MERAL BEKSAÇ'IN ÖZGEÇMİŞİ

Soyadı, adı : BEKSAÇ , MERAL

Doğum tarihi, ay ve gün : 25 EKİM 1956

Eğitimi ve Akademik Ünvanları :

Haziran 1974 : Ankara Fen Lisesi, Ankara.

Haziran 1980 : Tıp Fakültesi , Hacettepe Üniversitesi,Ankara,

Kasım 1985 : İç Hastalıkları Uzmanlığı,Hacettepe Tıp Fakültesi,Ankara.

Ekim 1987 :İç Hastalıkları Doçentliği (Y.İ.H.de mecburi hizmet bitiminde)

Eylül 1991 :Hematoloji Uzmanlığı,Ankara Üniversitesi Tıp Fakültesi, Ankara,

Temmuz 1993 : Hematoloji Profesörlüğü, Ankara Üniversitesi

Ocak 1995 den itibaren : Türkiye Bilimler Akademisi Üyesi (2004 den beri asli üye)

Şimdiki görev(ler)i :

Ankara Tıp Fakültesi Hematoloji Bilim Dalı öğretim üyesi (1989-)

Ankara Tıp Fakültesi Akraba Dışı Doku Bankası kurucu ve sorumlu öğretim üyesi (2006-)

Ankara Tıp Fakültesi Kordon Kanı Bankası sorumlu öğretim üyesi (2006-)

Türkiye kemik iliği Transplantasyon Vakfı Başkanı (2012-)

Hematoloji Bilim Dalı Hematodiagnostik Yüksek Lisans Programı yürütücüsü, Doku Tiplendirme laboratuvarı kurucu sorumlusu (EFI ve sağlık Bakanlığı nezdinde)

International Myeloma Foundation - Scientific Advisory Board üyeliği

European Myeloma Network Clinical trialists Board üyeliği

Türkiye Lenfoma-Miyeloma Derneği Miyelom Çalışma Grubu başkanlığı

Türkiye Bilimler Akademisi Kök Hücre Grubu üyeliği

Sağlık Bakanlığı Transplantasyon İmmunoloji Danışma Kurulu üyeliği

World Marrow Donors Association education Committee üyeliđi

Bayırdır Tıp ve Novartis Onkoloji Ödülleri jüri üyelikleri

Geçmişteki en önemli görev(ler)i :

2002-2005: Sağlık Bakanlığı Ulusal Kordon kanı bankacılığı danışma kurulu kurucu üyeliđi

1995-2005: Hematoloji Bilim Dalı Laboratuvarı sorumlu öğretim üyesi

1999-2001 : Türk Hematoloji Derneđi Erişkin Hematolojik Onkoloji Alt Komite(Turkish Leukemia Study Group) Başkanlığı

2001-2006: Multipl Miyeloma Alt Komite Başkanlığı

Ağustos 2006: Institute of Cancer Research, Londra: misafir araştırmacı

Temmuz 2005- Ağustos 2005: Stanford Üniversitesi Kemik İliđi Transplantasyon Merkezi: misafir hekim

Temmuz 2001-Ağustos 2001: Stanford Üniversitesi Kemik İliđi Transplantasyon Merkezi- misafir hekim.

Temmuz 2000-Ağustos 2000: Cedars Sinai Health Center ,Myeloma Program, UCLA, misafir profesör

Temmuz 1999-Ağustos 1999: New York Medical College, Cancer Comprehensive Center, misafir araştırmacı

Temmuz 1998-Ağustos 1998: West Los Angeles VA Medical Center, UCLA, Department of Medical Oncology- misafir araştırmacı

Temmuz 1997-Ağustos 1997: Dana Farber Cancer Research Center, Core Flow Cytometry ve Harvard Medical School Department of Pharmacology ,Boston- misafir araştırmacı

1986-1990 :T.Yüksek İhtisas Hastanesi Hematoloji-İmmunoloji Laboratuvarları kurucu ve yöneticisi

Mart 9, 1983-Mayıs 30, 1984: Karolinska Hastanesi, Hematoloji Departmanı, , Stockholm- misafir araştırma görevlisi (Hacettepe Üniversitesinden izinli olarak)

Kazanılmış bilimsel ödüller :

1973 Türkiye Bilimsel ve Teknik Araştırma Kurumu , proje yarışması , üçüncülük ödülü.

1986 Türk Kanser Araştırma ve Savaş Kurumu “ Kaymakçalan” Bilim ödülü

Birçok kez çeşitli ulusal kongrelerde en iyi araştırma ödülü,

En başarılı araştırma ödülü, Türk Hematoloji Derneği, 2015

Best basic science abstract in multiple myeloma, The center for lymphoma and myeloma, New York, AMERİKA BİRLEŞİK DEVLETLERİ, Ekim 2017

En Başarılı Laboratuvar Hematolojisi Araştırma Ödülü, Türk Hematoloji Derneği, Ekim 2017

“Kır2ds4’ün Miyelom Plazma Hücrelerine Karşı Otolog Veya Kordon Kanı Doğal Öldürücü Hücre Aracılıklı Toksikitede Rolü” Türk Hematoloji Derneği Bildiri Ödülü

“Misafir profesörlük ödülü” Nanjing Municipal Hospital of TCM, ÇİN HALK CUMHURİYETİ

Bilimsel dergilerin editörler kuruluna üyelikler :

Bone Marrow Transplantation,
Yurt içinde 5 adet Üniversite yayın organı ve bağımsız dergide
Advances in Hematology: editorler kurulu üyeliği

Bilimsel derneklere üyelikler;

1. European Blood - Marrow Transplantation Group (EBMT),(1991-)
2. International Bone Marrow Transplantation Registry (IBMTR) (1992-)
3. International Society of Hematology (ISH), (1992-)
4. European Association for Hematology (EHA),(1994-)
5. European Organisation for Cancer Research and Treatment-Leukemia Cooperative Group (EORTC-LCG) (1991-)
6. Türk Hematoloji Derneği (THD)(1990-)
7. Türk Kemik İliği Transplantasyon Vakfı Kurucu Üyesi(1990 -) ve Yönetim Kurulu Başkanı (2001 -2004, 2012-)
8. American Society of Blood and Marrow Transplantation(ASBMT)(2008-)
9. American Society of Hematology (ASH) (1991-)
10. International Myeloma Foundation (2000-)
11. European Federation of Immunogenetics (EFI)(2000-)
12. World Marrow Donors Association (WMDA) (2000-)
13. Türkiye Lenfoma_Miyeloma Derneği (2010-)
14. European Myeloma Network kurucu üyelik (2004-)
15. International Myeloma Society (2009-)

16. Balkan Myeloma Study Group vice president(2017-)
17. EHA Congress Scinetific Committee, Üye, 2014-2017
18. Türk Hematoloji Derneği İmmunohematoloji çalışma grubu başkanlığı (2016-)

Projeler:

Tübitak Projesi:

- Granulosit Koloni Stimulating Faktor Kullanılarak Mobilize Edilmiş Kemik İliği Hücrelerinin Spinal Kord Yaralanmasından sonra İyileşmeye Olan Etkinliğinin in-vivo ve ex vivo olarak takip edilmesi (2005-2009)
- Kordon kanı, maternal plazma ve amniyon sıvısındaki sitokin seviyelerinin serolojik ve moleküler yöntemlerle belirlenmesi ve kordon kanı in vitro koloni oluşturma potansiyeline etkisi, Yürütücü, , 25/11/2016 (Devam Ediyor)
- İnsan Göbek Kordon Kanı Progenitör Hücre İçerisinin Fenotipik ve Fonksiyonel Yöntemlerle Belirlenip Aralarındaki İlişkinin Araştırılması, Danışman, 01/10/2014 - 01/10/2015
- Killer Immunoglobulin Like Reseptör Genotipinin Kordon Kanı kaynaklı Doğal İldürücü Hücrelerinin in vitro anti-miyelom yanıtı etkisi ve otolog anti-miyelom etki ile karşılaştırılması, Danışman, 01/10/2015-01.10.2017
- İnsan Göbek Kordon Kanı progenitör Kök Hücre İçerisinin fenotipik ve fonksiyonel yöntemlerle belirlenip aralarındaki ilişkinin araştırılması, Yürütücü, 01/10/2014 - 01/10/2015
- Spinal Kord zedelenmesi sonrası ezyon bölgesine kemik ilgi kaynaklı mononükleer hücrelerin implantasyonunun in vivo ve in vitro izlenmesi, Yönetici, 2005-2008
- Hematolojik Kanselerde (MM ve KML) hücre döngüsünü düzenleyen siklin bağımlı kinaz ve inhibitörlerinin akım sitometrik analizi, TÜBİTAK PROJESİ, Yönetici, 2000-2002
- Candidaların çoğul ilaç dirençliliğinde mdr1 gen ifadesinin rolü , Yönetici, 1995-1998

Türkiye Japonya ortak araştırma projesi

Kordon Kanından Kök Hücre Eldesi İçin Kullanılan Otomatize Sepax (Biosafe) Sistemi İle Yeni Geliştirilen Manuel Filtrasyon Bazlı Deplesyon Sisteminin Karşılaştırmalı Olarak Değerlendirilmesi, yürütücü, 26.01.2015-28.07.2015

DPT Projesi: Ankara Üniversitesi Kordon Kanı, Kan ve Kök Hücre Bankası Kamu Altyapı Projesi, Yürütücü, 15.01.2009-23.12.2010

Kalkınma Bakanlığı Projesi:

Kordon kanından biyoteknolojik hücresel ürün geliştirme altyapısı, Kalkınma Bakanlığı, Yönetici, 31/03/2016 (Devam Ediyor)

Ankara Üniversitesi BAP projesi :

AÜTF Kordon Kanı Bankası sürdürülebilirlik projesi Ankara Üniversitesi Akraha Dışı Kordon Kanı Bankası alt yapı devamlılığı projesi, Yükseköğretim Kurumları tarafından destekli bilimsel araştırma projesi, Yürütücü 18.08.2011-18.08.2014

Erken Gebelik Kayıpları ve Yüksek Riskli Gebeliklerin İmmünogenetik Açısından İncelenmesi, Araştırmacı, BAP Projesi, 04.08.2017- , Proje No: THD-2017-14660 (devam ediyor). Örnek sayısı artırılıyor. Hacettepe Üniversitesi ile ortak bir tez çalışması.

Kitap ve kitap bölümleri:

- Molecular methods in stem cell transplantation (Humana Press): Editor: Meral Beksac Nisan 2007
Aynı kitaptan bölümler:
 1. Sequence Specific Primed PCR (PCR-SSP) Typing of HLA Class I and Class II Alleles (K. Dalva, M. Beksac, Ankara, Turkey).
 2. HLA typing with Sequence Specific Oligonucleotide Primed PCR(PCR-SSOP) and use of the Luminex™ technology (K. Dalva, M. Beksac, Ankara, Turkey)
 3. Application of Immunohistochemistry and Fluorescent In Situ Hybridization for detection of Donor Type Cells: (I. Kuzu, M. Beksac, Ankara,Turkey)
- 4. Türkiye Klinikleri Hematoloji Özel Dergisi: **Beksac M**, “Renal-Anlamalı Monoklonal Gammopati” Türkiye Klinikleri J Hematol-Special Topics 2018;11(2):173-7
- 5. Türkiye Klinikleri Hematoloji Özel Dergisi: Yurdakul P, Karadağ FK, **Beksac M**, “Kordon Kanı Bankacılığı ve Kordon Kanı Nakilleri” Türkiye Klinikleri J Hematol-Special Topics 2018;11(1):60-7
- 6. Hematopoetik Kök Hücre Nakli Kitabı: Karadağ, F.K., Yurdakul, P., Beksac M., “Kordon Kanı Bankacılığı Ve Transplantasyonu” Türk Hematoloji Derneği OCAK 2019;12(1):144-153

Yayımlar:

1. Erdogan M, Inal A, Ozgu M, Beksac MS, Ergurbuz I. Effect of oral contraceptive (ethinyl estradiol and d-norgestrel) on serum prolactin-oestradiol and progesterone levels Acta Reprod Turc. 1980 Jan;1(3):85-91.
2. **Beksaç M.S.**, Kişnişçi H.A., Çakar A.N. and **Beksaç M.**: The endocrinological evaluation of bilateral and unilateral oophorectomy in premenopausal women. Int. J. of Fertility 28: 219-224, 1983.
3. **Beksaç M.S.**, **Beksaç M.**, Kişnişçi H.A. and Kökçü A.: Stress induced release of cortisol and prolactin during dilatation and curettage under general and local anesthesia. Neuropsychobiology 11: 227-228, 1984.

4. **Beksaç M.**, Porwit Ksiazek A., Hast R., Biberfeld P. and Reizenstein P.: Cytotoxicity of monoclonal antibodies against individually immunophenotyped human leukemic cells. *Cancer Immunology Immunotherapy* 19: 231-236, 1985.
5. **Beksaç M.**, Peterson C. and Reizenstein P.: Decreased retention of vinca alkaloids in chronic lymphatic leukemia cells from refractory patients. *Cancer Chemotherapy and Pharmacology* 15. 72-75, 1985.
6. Reizenstein P., **Beksaç M.**, Biberfeld P., Christensson B., Lagerlöf B., Lauren L., Öst A. and Porwit Ksiazek A. Leukemic myeloblasts expressing lymphoid markers. *Acta Hematologica* 74: 148-150, 1985.
7. Hast R., **Beksaç M.**, Axdorf S., Sjögren A.M., Öst A. and Reizenstein P.: Effect of retinoids on in vitro differentiation of bone marrow cells in the myelodysplastic syndrome. *Medical Oncology and Tumor Pharmacotherapy* 3: 35-38, 1986.
8. Ösby E., **Beksaç M.**, and Reizenstein P.: Alternating combination therapy does not delay development of refractoriness in myeloma. *Anticancer Research* 6:1145-1148, 1986.
9. **Beksaç M.**, Kansu E, Kars A, İbrahimoğlu Z, Fırat D: A rapid drug sensitivity assay for neoplastic cells. *Med Oncol Tumour Pharmacother.*5:253-257 , 1988
10. **Beksaç M.**, Akan H., Koç H., İlhan O., Ertürk P., Güneşli A., İkizünal Y., Şardaş O.S.: P-Glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporin A containing protocols. *Medical Oncology and Tumor Pharmacotherapy* 9 (2); 101-105, 1992.
11. Karakaya A., Tuncel N., Yücesoy B., Akın M., Çuhruk H., Şardaş O.S., **Beksaç M.**: The effects of volatile anesthetic agents on human immune system function via occupational exposure. *Immunopharm. Immunotoxicol* 14 (182): 251-259, 1992.
12. **Beksaç M.**, Dalva K., Gönenç F., Dalva I., Gariboğlu S., Batur N., Çetin S.: Soluble CD23 and Interleukin 2 receptor levels in renal allograft recipients. *Transplantation Proceedings* 25(2) (April) : 3043-3045, 1993.
13. **Beksaç M.**, Ertürk Ş., Akan H., Koç H., İlhan O.: The clinical correlations of serum tumor necrosis factor alpha in acute leukemias. A predictor of response and relapse? *Leukemia* 7(11): 1773-1776, 1993.
14. Akan H., Koç H., **Beksaç M.**, İlhan O., Gürman G., Aydoğdu İ., Şardaş O.S.: Case report : complications of bone marrow transplantation ; a long way to run . *Libri Oncol.* 22(3) : 219-221 ,1993.
15. Akan H., **Beksaç M.**, Aydoğdu İ., Koç H., İlhan O., Özcan M.: Peripheral T cell receptors α, β and γ, δ in Hodgkin's Lymphoma. *Br. J. Haematol.* 87:544-547, 1994

16. İlhan O, Uysal A, Aydoğdu İ, **Beksaç M**, Akan H, Koç H: Mitoxantrone and cytosine arabinoside in previously untreated patients with acute non-lymphocytic leukemia. *Haematologica* 27(2):93-97, 1996
17. Arslan Ö, Akan H, Koç H, **Beksaç M**, İlhan O, Özcan M, Yalçın S, Gürman G, Konuk N, Uysal A Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen. *Bone Marrow Transplantation* 18:261-264, 1996
18. İlhan O, Koç H, Akan H, Gürman G, Arslan Ö, Özcan M, Arıkan N, Sencer H, Konuk N, Uysal A, **Beksaç M**. Hemorrhagic cystitis as a complication of bone marrow transplantation. *J of Chemotherapy* 9:56-61, 1996
19. Akan H, Koç H, Arslan Ö, **Beksaç M**, İlhan O, Gürman G, Özcan M. Febrile neutropenia in a bone marrow transplantation center. *Int J of Antimicrob Agents* 8:127-130 1997
20. İlhan O, Akan H, Koç H, Gürman G, Arslan Ö, Özcan M, Erdi H, Erdem C, Konuk N, Uysal A, **Beksaç M** .Incidence of graft versus host disease in allogeneic bone marrow transplantation in a single center study from Turkey. *Hematol Cell Ther* 39:133-36, 1997
21. **Beksaç M**, Beksaç MS, Tipi VB, Duru HA, Karakaş MÜ, Çakar AN. An artificial intelligent diagnostic system on differential recognition of hematopoietic cells from microscopic images. *Cytometry (Communications in clinical cytometry)* 30:145-150, 1997.
22. Üstün C, Koç H, Karayalçın S, Akyol G, Gürman G, İlhan O, Akan H, Özcan M, Arslan Ö, Konuk N, Uysal A, **Beksaç M**. Hepatitis B virus infection in allogeneic bone marrow transplantation. *Bone Marrow Transplant* 20, 289-196, 1997
23. Koç H, Arslan Ö, Gürman G, Akan H, Özcan M, İlhan O, Aydoğdu İ, Arat M, **Beksaç M**, Konuk N, Uysal A. The use of high dose chemotherapy plus granulocyte colony stimulating factor for the salvage of refractory or resistant relapse malignant lymphoma patients without stem cell support. *Acta Haematol* 98(3):136-139 1997
24. Koç H, Gürman G, Arslan Ö, Özcan M, Akan H, İlhan O, Konuk N, **Beksaç M**, Uysal A. Allogeneic peripheral blood stem cell transplantation. Is there an increased risk of GVHD in leukemia patients. *J of Chemother* 9(5):371-376 1997
25. İlhan O, **Beksac M**, Arslan Ö, Özcan M, Koç H, Akan H. HLA DR2 a predictive marker in response to cyclosporine therapy in aplastic anemia. *Int J Hematol* 66:291-295, 1997
26. Üstün C, Karavelioğlu D, İlhan O, Aydınтуğ O, **Beksaç M** . A case report of a patient who has pure red cell aplasia and rheumatoid arthritis *Int J Hematol* 66:505-512, 1997.
27. Arslan Ö, Gürman G, Dilek İ, Özcan M, Koç H, İlhan O, Akan H, Konuk N, Uysal A, **Beksaç M**. Incidence of tuberculosis after bone marrow transplantation in a single center from Turkey and review of the literature. *Hematologia* .29(2):133-7,1998.

28. Dilek İ, Koç H, Demirer T, Anadolu R, Üstün C, **Beksaç M**, Erdi H, Özcan M, Akan H. Acquired ichthyosis (superimposed upon chronic graft-versus-host disease) following an allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia "a case report" Bone Marrow Transplant .21(11):1159-61,1998
29. **Beksaç M**, Arslan Ö, Koç H, Akan H, İlhan O, Arat M, Özcan M, Gürman G, Konuk N, Uysal. Randomized unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukemia. Medical Oncol .15:183 -190, 1998
30. Arslan Ö, Üstün C, Arat M, Çelebi H, Akan H, **Beksaç M**, İlhan O, Gürman G, Özcan M, Konuk N, Uysal A, Koç H. .Allogeneic peripheral blood stem cell transplantation in acute nonlymphoblastic leukemia.Hematol.Oncol. 16(4):155-62,1998.
31. Üstün C, Arslan Ö, **Beksaç M**, Koç H, Gürman G, Özçelik T, Yılmaz B, İlhan O, Akan H, Özcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek İ, Çelebi H, Coşkun HŞ. A retrospective comparison of allogeneic peripheral stem cell and bone marrow transplantation .Results from a single center, a focus on the incidence of GVHD and relapse. Biol Blood Marrow Transplant. 5(1):28-35, 1999.
32. Aydoğdu İ, İlhan O, **Beksaç M**, Koç H, Akan H, Konuk N, Uysal A..Serum erythropoietin levels in patients with leukemia on cytostatic treatment. Hematologia (Budap) 29(2):133-7,1998
33. Miniero R, Rocha V, Saracco P , Locatelli F , Brichard B, Nagler A, Roberts I, Yaniv I , **Beksac M**, Bernaudin F , Gluckman E on behalf of Eurocord.Cord blood transplantation in hemoglobinopathies. Bone Marrow Transpl 22 (Suppl 1): S78-S79 , 1998
34. Üstün C, İdilman R, Gürman G, Özcan M, Akyol G, Akan H, İlhan O, **Beksaç M**, Uysal A, Konuk N, Karayalcın S, Poyraz A, Van Thiel D, Koç H..Hematopoietic stem cell transplantation from non-replicative hepatitisB virus carriers is safe.J Hepatol.31:202-209,1999.
35. Üstün C, Özcan M, Gürman G, Çakır M, Erekuş S, Akyol G, Arat M, Çelebi H, İdilman R, Akan H, İlhan O, **Beksaç M**, Koç H. Differences in liver pathology and clinical outcome between two patients with hepatitis B virus and graft versus host disease. Pathol Oncol Res. 5(3): 229-32,1999.
36. Nergizoğlu G, Keven K, Ateş K, Üstün C, Tolunay Ö, **Beksaç M**, Karatan O, Ertuğ AE. Chronic graft versus host disease complicated by membranous glomerulonephritis. Nephrol Dial Transplant 14(10):2461-3,1999.
37. İlhan O, Arslan Ö, Arat M, **Beksaç M**, Akan H, Özcan M, Gürman G, Konuk N, Uysal A, Koç H. The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. Transfus Sci. 20(1):69-71,1999.

38. **Beksaç M**, Arat M, Akan H, İlhan O, Koç H, Özcan M. Circulating CD44 and ICAM-1 levels in patients with low grade NHL and CLL responsive or nonresponsive to interferon-alpha. *Cancer* 89(7):1474-1481,2000.
39. Arslan Ö, Akan H, Arat M, Dalva K, Özcan M, Gürman G, İlhan O, Konuk N, **Beksaç M**, Uysal A, Koç H. Soluble adhesion molecules (s ICAM-1, I-selectin, e-selectin, sCD44) in healthy allogeneic peripheral stem cell donors primed with recombinant G-CSF. *Cytotherapy* 2(4): 259-265,2000.
40. Arslan Ö, Coşkun HS, Arat M, Çelebi H, Özcan M, Gürman G, Üstün C, Demirer T, Akan H, İlhan O, Konuk N, **Beksaç M**, Uysal A, Koç H. Allogeneic peripheral blood stem cell transplantation for standard risk leukemias: Four years experience of İbni Sina Hospital .*Bone Marrow Transplant* 25: 1229-1232, 2000
41. Akan H, Güven N, Aydoğdu I, Arat M, **Beksaç M**, Dalva K. Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. *Acta Haematol* 103: 152-156, 2000.
42. Ma HJ, Sjak-Shie NN, Vescio RA, Kaminsky M, Mikail A, Pold M, Parker K, **Beksaç M**, Belson D, Moss JJ, Wu CH, Zhou J, Zhang L, Chen G, Said JW, Berenson JR. Human herpes virus 8 open reading frame 26 and open reading frame 65 sequences from multiple myeloma patients: a shared pattern not found in Kaposi's sarcoma or primary effusion lymphoma. *Clin Cancer Res.* 6(11): 4226-33,2000.
43. **Beksaç M**, Ma M, Akyerli C, Der Danielian M, Zhang L, Liu J, Arat M, Konuk N, Koc H, Özçelik T, Vescio H, Berenson JR. Frequent demonstration of Human herpes Virus 8 in bone marrow biopsy samples from Turkish patients with multiple myeloma. *Leukemia* ;15(8):1268-73. 2001
44. Sonneveld P, S. Suci, Weijermans P, **Beksaç M**, Neuwirtova R, Solbu , Lokhorst H, van der Lelie, Dohner H, Gerhartz H, Segeren CM, Willemze R, Löwenberg B. Cyclosporin A combined with vincristine, doxorubicin, and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). *Br J Haem.* 115: 895-902,2001.
45. G. Ongun, Halıcı U, Leblebicioğlu K, Atalay V, **Beksaç M**, Beksaç S. Automated colour detection in blood cell images by an efficient snake algorithm. *Nonlinear analysis: Series B-Applications.* 47: 5839-5847,2001.
46. Gürman G, Dilek I, Arslan O, Arat M, **Beksaç M**, İlhan O, Özcan M, Akan H, Dalva K, Konuk N, Uysal A, Koç H. The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation. *Transfus Apheresis Sci.* 2001 Feb;24(1):23-8.
47. Arat M, Arslan O, **Beksaç M**, Keven K, Nergizoglu G, Erturk S. Hematopoietic cell transplantation-related nephropathy (letter). *Am J Kidney Dis.* 38(1):218-9,2001.

48. Ozcan M, Ustun C, Akcaglayan E, Akan H, Arslan O, İlhan O, **Beksaç M**, Gurman G, Demirer T, Arat M, Celebi H, Konuk N, Uysal A, Koc H. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 27(5):499-505, 2001.
49. Gurman G, Celebi H, Ustun C, Arat M, İlhan O, Ozcan M, Arslan O, Uysal A, Akan H, **Beksac M**, Konuk N, Koc H. Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia. *Ther Apher. Feb;5(1):54-7*, 2001.
50. Ustun C; **Beksac M**; Dalva K; Koc H; Konuk N; İlhan O; Ozcan M; Topcuoglu P; Sertkaya D; Hayran M .In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia *Med Oncol* 19(1): 59-67 . 2002.
51. Schmitz N, **Beksac M.**, Hasenclever D.,Bacigalupo A., Ruutu T., Nagler A., Gluckman E.,Russell N.,Apperley J.F., Gorin N.C.,Szer J.,Bradstock K.,Buzyn A.,Clark P.,Borkett K.Gratwohl A. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. *Blood* 100(3):761-767,2002.
52. **Beksac M.** et al. The role of pretransplant Interferon –alpha treatment on the outcome of stem cell transplantation from related donors in chronic myelogenous leukemia. *Bone Marrow Transpl* 31 (10): 897-904 ,2003.
53. Kutlay S, **Beksac M**, Dalva K, et al. The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia. *Leukemia Lymphoma* 44 (5): 791-795, 2003 .
54. Favre G, **Beksac M**, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. *Bone Marrow Transpl* 32 (9): 873-880 Nov 2003 .
55. Gorin NC, Labopin M, Rocha V, et al. Marrow versus peripheral blood for genotypical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. *Blood* 102 (8): 3043-3051, Oct 2003.
56. Sanli H, Ekmekci P, Kusak F, et al. Hyperkeratosis of the nipple associated with chronic graft versus host disease after allogeneic haematopoietic cell transplantation . *Acta Derm-Venereol* 83 (5): 385-386 , 2003.
57. Kuzu I, **Beksac M**, Arat M, Celebi C, İlhan A, Ereku S. Bone Marrow Microvessel Density (MVD) In adult Acute Myeloid Leukemia (AML): Therapy induced changes and effects on survival. *Leukemia Lymphoma* , 44(5): 791-795, 2004.

58. İlhan O, Arat M, Arslan O, Ayyıldız E, Sanlı H, **Beksac M**, Özcan M, Gürman G, Akan H. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. *Transfus Apheresis Sci.* 30(3):185-7, 2004.
59. İdilman R, Arat M, Soydan E et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. *J Viral Hepat.* 11(2):141-7, 2004.
60. Akyerli C, **Beksac M**, Holkoc M, Frevelc M, Dalva K, Özbek U, Soydan E, Özcan M, Özet G, İlhan O, Gürman G, Akan H, Williams B, Özçelik T. Expression of IFITM1 in Chronic Myeloid Leukemia patients. *Leuk Res* 29(3):283-286,2005.
61. Schmitz N, **Beksac M**, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley J, Szerm J, Bradstock K, Buzyn A, Schlegelberger B, Matcham J, Gratwohl A. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. *Haematologica.* ;90(5):643-8,2005.
62. Zwierzina H, Suci S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, **Beksac M**, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. *Leukemia.* 2005 Nov;19(11):1929-33.
63. Bakanay SM, Dalva K, Arat M, Arslan O, Ayyıldız E, **Beksac M**, İlhan O. Does continuous flow apheresis influence viability in allogeneic hematopoietic stem cell harvest? *Transf. Apher.Sci.* 2006 Apr;34(2):171-8. Epub 2006 Mar 20.
64. İdilman R, Kuzu I, Erden E, Arat M, Soydan E, Soykan I, Akyol G, Karayalcin S, Akan H, **Beksac M** Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation. *Bone Marrow Transplant.* 2006 Jan;37(2):199-206.
65. B G M Durie, J-L Harousseau, J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, **M Beksac**, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan and S V Rajkumar on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. *Leukemia.*2006 ,20(9):1467-73. Epub 2006 Jul 20.
66. Wu KL, **Beksac M**, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. *Haematologica.* 2006 Dec;91(12):1722-3.

67. Ali R.;**Beksac M.**;Ozkalemkas F.;Ozkocaman V.;Ozkan;Ozcelik;Tunali A. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. *Leuk Lymph* 2007; 48(7):1426-8.

68. Ludwig H, Durie B.G.M., Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, **Beksac M**, Boccadoro M, Barlogie B, Shustik C, Cavo M, Joshua D, Attal M, Crowley J, Sonneveld P. Favorable prognostic features of young patients with multiple myeloma account for longer survival after conventional or high-dose therapy. *Blood* 2008 Apr 15;111(8):4039-47. Epub 2008 Feb 11.

69. Rawstron AC, Orfao A, **Beksac M**, Bezdicikova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggieri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. *Haematologica*. 2008 Mar;93(3):431-8.

70. **Beksaç M.**, Delforge M.,Richardson P.The evolving treatment paradigm of multiple myeloma: From past to present and future.(Sürekli gelişmekte olan bir tedavi yaklaşımı: Multipl miyeloma tedavisinin geçmişi, bugünü ve geleceği) *Turk J Hematol* 2008 ;25(2): 60-

71. Ozet A., Guran S., **Beksaç M.** Familial multiple myeloma associated with chronic inflammation: First report from Turkey. *Clin Lymph Myeloma*.2008;8(4):246-8.

72. Sanli H, Akay BN, Arat M, Koçyigit P, Akan H, **Beksac M**, Ilhan O.Vitiligo after hematopoietic cell transplantation: six cases and review of the literature. *Dermatology*. 2008;216(4):349-54.

73. Brand A, Rebutta P, Engelfriet CP, Reesink HW, Beguin Y, Baudoux E, Kögler G, Ebrahimi M, Grazzini G, Costa AN, Bosi A, Sacchi N, Lombardini L, Pupella S, Lecchi L, Garcidueñas ED, van Beckhoven JM, de Wit HJ, Fibbe WE, Zhiburt EB, Bart T, **Beksaç M**, Navarrete C, Regan F. International forum: cord blood banking. *Vox Sanguinis* 2008; 95(4):335-48.

74. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, **Beksac M**, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of Multiple Myeloma. *Leukemia*. 2009 ;23(9):1545-56.

75. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, arlogie B,Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer

O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. Collaborators: Alexanian R, Anderson K, Attal M, Avet-Loiseau H, Badros A, Bergsagel L, Blade J, Barlogie B, Batille R, **Beksac M**, Belch A, Bensinger B, Boccadoro M, Cavo M, Chen WM, Child T, Chim J, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimipoulous M, Dispenzieri A, Einsele H, Facon T, Fantl D, Femand JP, Fonseca R, Gahrton G, Gertz M, Gibson J, Goldschmidt H, Greipp P, Hajek R, Hardan I, Harousseau JL, Hata H, Hattori Y, Ho J, Hungria V, Hussein M, Ida S, Jacobs P, Jagannath S, Jian H, Joshua D, Kawano M, Kumar S, Kyle R, Lahuerta J, Lee JH, Lokhorst H, Ludwig H, LeLeu X, Maiolino A, Mehta J, Merlini G, Moreau P, Morgan G, Munshi N, Palumbo A, Pavlovsky S, Niesvizky R, Novis Y, Nouel A, Powles R, Pilarski L, Rajkumar SV, Reece D, Reiman T, Richardson P, Rodriguez A, Sezer O, Shaughnessy J, Shimizu K, Siegel D, Tricot G, San Miguel J, Singhal S, Sonneveld P, Shustik C, Spencer A, Stewart K, Tosi P, Turesson I, Van Ness B, Van Riet I, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Yehuda DB, Zonder J. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia* 2009; 23(2):215-24.

76. Shaw BE, Ball L, **Beksac M**, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M, Schmidt A, Yang E, van Walraven AM. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. *Bone Marrow Transplant*. 2010 ;45(5):832-8.

77. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, **Beksac M**, Hasenclever D, Socie G, Schmitz N. Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomized trial. *Lancet Oncol*. 2010;11(4):331-8.

78. Ludwig H, **Beksac M**, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. *Oncologist*. 2010;15(1):6-25.

79. **Beksac M**, Ridvan A, Ozcelik T, Ozcan M, Ozcebe O, Bayik M, Paydas S, Buyukasik Y, İlhan O, Ozkalemkas F, Gurman G, Uysal A, Akan H, Akcaglayan Soydan E, Tunalı A. Short and long term effects of granulocyte colony stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial. *Leuk Res* 2011;35(3):340-5.

80. **Beksac M**, Haznedar R, Tuglular T, Ozdogu H, İ. Aydogdu, N. Konuk, G. Aysucak, I. Kaygusuz, S. Karakus, E. Kaya, R. Ali, Z. Gulbas, G. Ozet, H. Goker, L. Undar. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. *Eur. J. Hematol*. 2011 ;86(1):16-22.

81. Attar A, Ayten M, Özdemir M, Özgencil E, Bozkurt M, Kaptanoğlu E, **Beksac M**, Kanpolat Y. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. *Cytotherapy* 2011;13(1):54-

82. Topcuoglu P, Arat M, Ozcan M, Arslan O, Ilhan O, **Beksac M**, Gurman G. *Ann Hematol*. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. *Ann Hematol*. 2011 ;5. [Epub ahead of print]

83. Abi-Rached L, Jobin MJ, Kulkarni S, McWhinnie A, Dalva K, Gragert L, Babrzadeh F, Gharizadeh B, Luo M, Plummer FA, Kimani J, Carrington M, Middleton D, Rajalingam R, **Beksac M**, Marsh SG, Maiers M, Guethlein LA, Tavoularis S, Little AM, Green RE, Norman PJ, Parham P .The shaping of modern human immune systems by multiregional admixture with archaic humans. *Science* . 2011 7;334(6052):89-94.

84. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hájek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, **Beksac M**, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). *Blood*. 2011 ;12 . [Epub ahead of print]

85 . Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; on behalf of the International Myeloma Working Group; International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, **Beksac M**, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczynszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N,

Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. *Leukemia*. 2011; 29. doi: 10.1038/leu.2011.196.

86. Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, **Beksac M**, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. *J Clin Oncol*. 2011 1;29(22):3016-22.

87. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, **Beksaç M**, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. *Blood*. 2011 4;118(5):1239-47.

88. Ludwig H, **Beksac M**, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. *Oncologist*. 2011;16(4):388-403.

89. Dimopoulos MA, Palumbo A, Attal M, **Beksaç M**, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau JL, da Costa FL, Ludwig H, Mellqvist UH, Morgan GJ, San-Miguel JF, Zweegman S, Sonneveld P. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. *Leukemia*. 2011;25(5):749-60.

90. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, **Beksaç M**, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giral S, Munshi NC, Jagannath S. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood*. 2011 5;117(18):4701-5.

91. **Beksac M**, Preffer F. Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic? *Bone Marrow Transplant*. 47(11):1391-6. doi: 10.1038/bmt.2011.240. Epub 2011 Dec 5,

92. Richardson PG, Delforge M, **Beksac M**, Wen P, Jongen JL, Sezer O, Terpos E, Munshi

N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orłowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. *Leukemia*. 2011 ;26(4):595-608.

93. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, **Beksac M**, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orłowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma. *Blood*. 2012;119(13):3003-15.

94. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kłoczko J, Bladé J, **Beksac M**, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med*. 2012 ;366(19):1759-69.

95. Bakanay SM, Serbest E, Dalva K, Kuzu I, Beksac M. Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto? *Case Report Med*. 2012;2012:319530.

96. Palumbo A, Waage A, Hulin C, **Beksac M**, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P. Safety of thalidomide in newly diagnosed elderly myeloma patients: an individual patient data meta-analysis of six randomized trials. *Haematologica*. 2013 Jan;98(1):87-94.

97. **Beksac M**, Dalva K. Role of killer immunoglobulin-like receptor and ligand matching in donor selection. *Bone Marrow Res*. 2012;2012:271695.

98. Ozdemir M, Attar A, Kuzu I, Ayten M, Ozgencil E, Bozkurt M, Dalva K, Uckan D, Kılıç E, Sancak T, Kanpolat Y, **Beksac M**. Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells. *Stem Cell Rev*. 2012 Sep;8(3):953-62.

100. Gupta V, Richards S, Rowe J; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. *Blood*. 2013 Jan 10;121(2):339-50.

101. Anghel R, Bachmann A, **Beksac M**, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Lang I, Marenca J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C. Expert opinion 2011 on the use of new anti-resorptive

agents in the prevention of skeletal-related events in metastatic bone disease. *Wien Klin Wochenschr.* 2013 Aug;125(15-16):439-47.

102. Dimopoulos MA, **Beksac M**, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R, Facon T. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. *Haematologica.* 2013 Aug;98(8):1264-72.

103. Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, **Beksac M**, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. *Blood.* 2013 Jun 20;121(25):5055-63.

104. Willemze R, Suci S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, **Beksac M**, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeyer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. *J Clin Oncol.* 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2. PubMed PMID: 24297940.

105. Morabito F, Bringhen S, Larocca A, Wijermans P, Mateos MV, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, Lahuerta JJ, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Turel AI, Liberati AM, Cavalli M, Rossi D, Passera R, Rosso S, **Beksac M**, Cavo M, Waage A, Miguel JS, Boccadoro M, Sonneveld P, Palumbo A, Offidani M. Bortezomib, Melphalan, Prednisone (VMP) versus Melphalan, Prednisone, Thalidomide (MPT) in elderly newly diagnosed Multiple Myeloma patients: A retrospective case-matched study. *Am J Hematol.* 2013 Nov 25. doi: 10.1002/ajh.23641. [Epub ahead of print] PubMed PMID: 24273190.

106. Jurczynszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Diaz AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MM, Atilla E, **Beksac M**, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani S, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. [Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.](#) Am J Hematol. 2016 Mar 8. 91(6): 575–580 doi: 10.1002/ajh.24351. [Epub ahead of print]

107. **Beksac M**, Yurdakul P. Front Med (Lausanne). 2016 Feb 17;3:7. doi: 10.3389/fmed.2016.00007. eCollection 2016. Review. [How to Improve Cord Blood Engraftment?](#) PMID:26925402

108. **Beksac M**. Front Med (Lausanne). 2016 Jan 11;2:95. doi: 10.3389/fmed.2015.00095. eCollection 2015. Review. [Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants?](#) PMID:26793711

109. Richardson PG, Hungria VT, Yoon SS, **Beksac M**, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. [Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.](#) Blood. 2016 Feb 11;127(6):713-21. doi: 10.1182/blood-2015-09-665018. Epub 2015 Dec 2. PMID:26631116

110. Hidayat AN, Aki-Yalcin E, **Beksac M**, Tian E, Usmani SZ, Ertan-Bolelli T, Yalcin [Insight into human protease activated receptor-1 as anticancer target by molecular modelling.](#) I.SAR QSAR Environ Res. 2015;26(10):795-807. doi: 10.1080/1062936X.2015.1095799. Epub 2015 Oct 26. PMID:26501801

111. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, **Beksac M**, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; [European Myeloma Network guidelines for the management of multiple myeloma-related complications.](#) European Myeloma Network. Haematologica. 2015 Oct;100(10):1254-66. doi: 10.3324/haematol.2014.117176. PMID: 26432383

112. Kalafat E, Yuce T, Konuralp B, Katlan DC, Kalaylioglu Z, **Beksac M**, Koc A, Soylemez F. [Effects of in utero cord blood collection on post-cesarean hemoglobin levels.](#) Eur J Obstet Gynecol Reprod Biol. 2015 Oct;193:123-6. doi: 10.1016/j.ejogrb.2015.07.022. Epub 2015 Aug 6. PMID:26295789

113. Beksac K, **Beksac M**, Dalva K, Karaagaoglu E, Tirnaksiz MB [Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among](#)

[Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival.](#) PLoS One. 2015 Jul 16;10(7):e0132526. doi: 10.1371/journal.pone.0132526. eCollection 2015. PMID: 26181663

114. Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, **Beksac M**, Alsina M, San-Miguel JF. [Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.](#) Expert Rev Anticancer Ther. 2015;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7. Erratum in: [Expert Rev Anticancer Ther. 2015;15\(9\):1121.](#) PMID:26051506

115. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, **Beksac M**, Spencer A, Oakervee H, Orłowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. [Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.](#) N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. PMID:26035255

116. **Beksac M**, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Firatlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A. [Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.](#) Acta Haematol. 2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24. PMID: 2582429

117. Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, **Beksac M**, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. [Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.](#) Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26. PMID:25621805

118. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, **Beksac M**, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. [International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.](#) Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review. PMID: 25439696

119. Scheid C, Reece D, **Beksac M**, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK. [Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t\(4;14\) translocation.](#) Eur J Haematol. 2015 Oct;95(4):316-24. doi: 10.1111/ejh.12491. Epub 2015 Jan 22. PMID:25402977

120. San-Miguel JF, Hungria VT, Yoon SS, **Beksac M**, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee

JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. [Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.](#) *Lancet Oncol.* 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: *Lancet Oncol.* 2015 Jan;16(1):e6. PMID:25242045

121. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, **Beksac M**, Field S, Yang H, Shaw BE; World Marrow Donor Association Clinical Working Group Committee. [Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee.](#) *Bone Marrow Transplant.* 2014 Jul;49(7):880-6. doi: 10.1038/bmt.2014.67. Epub 2014 Apr 7. PMID:24710563

122. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, **Beksac M**, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. [European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.](#) *Haematologica.* 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358. PMID:24497560

123. Paul G. Richardson¹, Vânia T. M. Hungria², Sung-Soo Yoon³, Meral Beksac⁴, Meletios Athanasios Dimopoulos⁵, Ashraf Elghandour⁶, Wieslaw W. Jedrzejczak⁷, Andreas Guenther⁸, Thanyaphong Na Nakorn⁹, Noppadol Siritanaratkul¹⁰, Robert L. Schlossman¹, Jian Hou¹¹, Philippe Moreau¹², Sagar Lonial¹³, Jae Hoon Lee¹⁴, Hermann Einsele¹⁵, Monika Sopala¹⁶, Bourras-Rezki Bengoudifa¹⁶, Claudia Corrado¹⁶, Florence Binlich¹⁷, and Jesús F. San-Miguel¹⁸ "Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment" Received 2015 Sep 8; Accepted Blood. 2016 Feb 11; 127(6): 713–721. Prepublished online 2015 Dec 2. doi: 10.1182/blood-2015-09-665018

124. Antonio Palumbo, M.D., Asher Chanan-Khan, M.D., Katja Weisel, M.D., Ajay K. Nooka, M.D., Tamas Masszi, M.D., Meral Beksac, M.D., Ivan Spicka, M.D., Vania Hungria, M.D., Markus Munder, M.D., Maria V. Mateos, M.D., Tomer M. Mark, M.D., Ming Qi, M.D., Jordan Schecter, M.D., Himlal Amin, B.S., Xiang Qin, M.S., William Deraedt, Ph.D., Tahamtan Ahmadi, M.D., Andrew Spencer, M.D., and Pieter Sonneveld, M.D., for the CASTOR Investigators "Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma" *N Engl J Med* 2016;375:754-66. DOI: 10.1056/NEJMoa1606038

125. Beksac M. Editorial: "How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?". *Front Med (Lausanne).* 2016 May 13;3:20. doi:10.3389/fmed.2016.00020. eCollection 17 şubat 2016. PubMed PMID: 27243013; PubMed Central PMCID: PMC4865490. 10.3389/fmed.2016.00007

126. Özen M, Üstün C, Öztürk B, Topçuoğlu P, Arat M, Gündüz M, Atilla E, Bolat G, Arslan Ö, Demirer T, Akan H, İlhan O, Beksaç M, Gürman G, Özcan M. "Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study". Turk J Haematol. 2016 Apr 18. doi: 10.4274/tjh.2015.0346. [Epub ahead of print] PubMed PMID: 27094579.

127. Özdemir NZ, Şahin U, Merter M, Gündüz M, Ateşgözoğlu B, Beksaç M. "A Case of Superwarfarin Poisoning due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker". Turk J Haematol. 2016 Sep 5;33(3):251-3. doi: 10.4274/tjh.2015.0433. PubMed PMID: 27093901.

128. Beksaç M, Gragert L, Fingerson S, Maiers M, Zhang MJ, Albrecht M, Zhong X, Cozen W, Dispenzieri A, Lonial S, Hari P. "HLA polymorphism and risk of multiple myeloma". Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print]

129. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksaç M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schechter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. "Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma". N Engl J Med. 2016 Aug 25;375(8):754-66.

130. San-Miguel JF, Hungria VT, Yoon SS, Beksaç M, Dimopoulos MA, Elghandour A, Jędrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. "Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial". Lancet Haematol. 2016 Oct 14. pii: S2352-3026(16)30147-8. doi:10.1016/S2352-3026(16)30147-8. [Epub ahead of print] PubMed PMID: 27751707.

131. Raje NS, Moreau P, Terpos E, Benboubker L, Grząsko N, Holstein SA, Oriol A, Huang SY, Beksaç M, Kuliczowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A. "Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma". Br J Haematol. 2016 Dec 22. doi:10.1111/bjh.14483. [Epub ahead of print] PubMed PMID: 28005265.

132. Gencer EB, Yurdakul P, Dalva K, Beksaç M. "Flow Cytometric Aldehyde Dehydrogenase (ALDH) Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment". Turk J Haematol. 2016 Dec 12. doi:10.4274/tjh.2016.0214. [Epub ahead of print] PubMed PMID: 27956370.

133. Sezer O, Beksaç M, Hajek R, Sucak G, Cagırgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timuragaoglu A, Dechow T, Lang A, Tuglular T, Drach J, Olie RA, Terpos E, "Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: A randomized phase 2 study.", Br J Haem, 176(5) 783-795. March 2017

134. Beksac M, Beksac S, Yucesoy M, Orgul G, Portakal O, "The Impact of 17B Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females", *Clinical and Experimental Health Sciences* 2017-06-19
135. Ilhan O, Arat M, Arslan O, Ayyıldız E, Sanlı H, Beksac M, Ozcan M, Gurman G, Akan H, "Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft versus host disease", *Transfusion Apheresis*, 2004 Jun;30(3):185-7.
136. Gündüz M, Ozen M, Şahin U, Toprak S.K, Bozdog S.C, Yüksel M, Arslan O, Ozcan M, Demirer T, Beksac M, Ilhan O, Gürman G, Topçuoğlu P, "Subsequent Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation", *Clin Transplant* 2017.
137. Ozkan T, Hekmatshoar Y, Ertan-Bolelli T, Hidayet AN, Beksac M, Aki-Yalçın E, "Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells." *Anticancer Agents Med. Chem.*, December 2017,
138. Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P, "Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth." *Br J Haem*, 178(6):896-905, September 2017
139. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG, "Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial." *Br J Haematol.*179(1):66-74, October 2017
140. Kumar SK, Dimopoulos MA, Kastiris E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM, "Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study." *Leukemia*, 31(11):2443-2448, November 2017
141. Atilla E, Atilla PA, Bozdog SC, Yüksel MK, Toprak SK, Topcuoglu P, Akay BN, Sanlı H, Akan H, Demirer T, Beksac M, Arslan O, Ozcan M, Gurman G, Ilhan O, "Extracorporeal photochemotherapy in mycosis fungoides." *Transfus Clin Biol.* 24(4):454-457, November 2017

142. Gencer EB, Yurdakul P, Dalva K, Beksac M, "Flow Cytometric Aldehyde Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment." *Turk J Haematol.* 1;34(4):314-320, Decenber 2017
143. Ozkan T, Hekmatshoar Y, Ertan-Bolelli T, Hidayat AN, Beksac M, Aki-Yalcin E, Yalcin I, Sunguroglu A. "Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells". *Anticancer Agents Med Chem.* 2017 Dec 29. doi: 10.2174/1871520618666171229222534. [Epub ahead of print] PubMed PMID: 29298654.
144. Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L. "Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel". *Journal of Hematology & Oncology.* 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1.
145. Sahin U, Dalva K, Gungor F, Ustun C, Beksac M. "Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation". *Ann Hematol.* 16 March 2018 97(6):1027-1039. doi: 10.1007/s00277-018-3274-0. Epub 2018 Mar 16.
146. Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P. "Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network." *Leukemia.* 2018 May 2, 32(7):1542-1560, doi: 10.1038/s41375-018-0040-1
147. Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastiris E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A "Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma". *Leuk Lymphoma.* ISSN: 1029-2403 2018 May 9 60:1, 163-171, DOI: 10.1080/10428194.2018.1459609
148. Weisel K, Sonneveld P, Spencer A, Beksac M, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A, "A Comparison of the Efficacy of Immunomodulatory-free Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis" *Clinical Lymphoma Myeloma and Leukemia,* ISSN: 1029-2403 Volume 18, Issue 3, 08 Nov 2018, Pages 163-173.e6 doi: 10.1016/j.clml.2017.12.011
149. Orgul G, Yucesoy HM, Portakal O, Beksac M, Beksac MS, "The Impact of 17B Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females" *Clinical And Experimental Health Sciences* Volume:8 Issue:2 Pages:118-121 DOI: 10.5152/clinexphealthsci.2017.432 JUN 2018

150. Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark T, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka A, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV, "Daratumumab Plus Bortezomib And Dexamethasone Versus Bortezomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of CASTOR" *Haematologica* 20 September 2018 *haematol* 2018. 103:12 2079-2087 194118; Doi:10.3324/haematol.2018.194118
151. Cengiz Seval G, Beksac M, "The safety of bortezomib for the treatment of multiple myeloma" *Expert Opin Drug Saf.* 2018 Sep 17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30.
152. Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Soledad Duran M, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pecelinas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbenyi Z, Abadi U, Pedersen RS, Feys C, Thoret-Bauchet F, Boccadoro M, "Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study" *Clinical Lymphoma Myeloma & Leukemia* October 2018 V: 18 I: 10 P: E401-E419 DOI: 10.1016/j.clml.2018.06.018
153. Atilla E, Yalciner M, Atilla PA, Ates C, Bozdog SC, Yuksel MK, Toprak SK, Gunduz M, Ozen M, Akan H, Demirer T, Arslan O, İlhan O, Beksac M, Ozcan M, Gurman G, Topcuoglu P, "Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?" *International medical press*, July 2018 doi: 2018;23(8):647-653. doi: 10.3851/IMP3252.
154. Tanaçan A, Yurdakul P, Aktöz F, Örgül G, Beksaç M, Beksaç MS, "Factors influencing the success of cord blood collection: a tertiary perinatal medicine center's experience" *Turkish Journal of Medical Sciences*, 2018 Oct 31;48(5):961-966 doi: 10.3906/sag-1802-54.
155. Arslan O, Elcin AE, Atilla E , Seker S, Baydin P , Gunduz M, Ozen M, Bayraktar UD, İlhan O , Beksac M, Elcin YM, Gurman G, "Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies" *Biology of Blood and Marrow Transplantation*, March 2018 24(3), S178-S179 DOI: <https://doi.org/10.1016/j.bbmt.2017.12.115>
156. Jurczynszyn A, Castillo J, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grzasko N, Milunovic V, Hus I, Madry K, Gaida Wa, Usnarska ZI, Debski J, Atilla E, Beksaç M, Mele G, Sawicki W, Jayabalan D, Charlinski G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungaria V, Richardson P, Laubach J, Guerrero GT, Liu J, Vesole DH, "Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients." *Leukemia & Lymphoma*, 2018 Jul ISSN: 1029 2403 60:1 118-123 doi: 10.1080/10428194.2018.1473574.
157. Atilla E, Özel F, Ataca Atilla P, Topçuoğlu P, Akan H, Beksaç M, İlhan O, Özcan M, Arslan Ö, Gürman G, Toprak SK, "Kronik Lenfositik Lösemide Tanı Anında Hipogammaglobulinemi

Sağkalım Ve Enfeksiyon Riski Üzerine Etkili midir?” Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, 2018 Ekim 20:3 doi: 10.24938/kutfd.439565

158. Ozkan T, Hekmatshoar Y, Ertan-Bolelli T, Hidayat AN, Beksac M, Aki-Yalcin E, Yalcin I, Sunguroglu A, “Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells” *Anti-Cancer Agents in Medicinal Chemistry*, 18(11):1521-1530 doi :10.2174/1871520618666171229222534

159. Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P. “Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network”. *Leukemia*. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review. PubMed PMID: 29251284.

160. Richardson, PG., Oriol, A., **Beksac, M.**, Liberati, A.M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., Miguel, JS., Sunami, K., O’Gorman, P., Sonneveld, P., Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov, T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M., on behalf of the OPTIMISMM trial investigators (2019) “Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.” *Lancet Oncol.* Jun 2019;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4.

161. Dimopoulos, M.A., Gay, F., Schjesvold, F., **Beksac, M.**, Hajek, R., Weisel, K.C., Goldschmidt, H., Maisnar, V., Moreau, P., Min C.K., Pluta, A., Chng, W.J., Kaiser, M., Zweegman, S., Mateos, M.V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A.B., Gupta, N., Labotka, R., Rajkumar, S.V., TOURMALINE-MM3 study group (2019) “Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial” *Lancet*. Jan 19 2019 393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4.

162. Weisel, K., Sonneveld, P., Spencer, A., **Beksac, M.**, Rizzo, M., Xu, Y.X., Fahrbach, K., Gaudig, M., Slavcev, M., Dearden, L., Lam, A (2019), “A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis” *LEUKEMIA & LYMPHOMA* JAN 2 2019, ISSN: 1029-2403 Volume: 60 Issue: 1 Pages: 151-162 DOI: 10.1080/10428194.2018.1466392

163. Jurczynszyn, A., Castillo, J.J., Avivi, I., Czepiel, J., Davila, J., Vij, R., Fiala, M.A., Gozzetti, A., Grzasko, N., Milunovic, V., Hus, I., Madry, K., Waszczuk-Gajda, A., Usnarska-Zubkiewicz, L., Debski, J., Atilla, E., **Beksac, M.**, Mele, G., Sawicki, W., Jayabalan, D., Charlinski, G., Szabo, A.G., Hajek, R., Delforge, M., Kopacz, A., Fantl, D., Waage, A., Crusoe, E., Hungria, V., Richardson, P., Laubach, J., Guerrero-Garcia, T., Liu, J.E.Q., Vesole, D.H (2019) “Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients” *LEUKEMIA*

&LYMPHOMA JAN 2 2019, ISSN; 1029-2403 Volume:60 Issue:1 Pages:118-123 DOI: 10.1080/10428194.2018.1473574

164. Kumar, S., Durie, B., Nahi, H., Vij, R., Dimopoulos, M.A., Kastiris, E., Terpos, E., Leleu, X., **Beksac, M.**, Goldschmidt, H., Hillengass, J., Su, Z., Hutton, B., Cameron, C., Khan, I., Lam, A (2019) "Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma" *LEUKEMIA & LYMPHOMA* JAN 2 2019 ISSN: 1029-2403 Volume: 60 Issue:1 Pages:163-71 DOI:10.1080/10428194.2018.1459609

165. Seval, G.C., Ozkan, E., **Beksac, M** (2019). "PET with Fluorodeoxyglucose F 18/ Computed Tomography as a staging Tool in Multiple Myeloma" *PET Clin. Jul;14(3):369-381.* doi: 10.1016/j.cpet.2019.03.009. Epub

166. Seval, G.C., **Beksac, M** (2019) "A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma" *Expert Opin Drug Saf.* 2019 May 9:1-9. doi: 10.1080/14740338.2019.1615051

167. Beksac MS, Fadiloglu E, Cakar AN, Gurbuz RH, Atilla, Onbasilar I, Beksac K, Katlan DC, Mumusoglu S, Calis P, Beksac M, "Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in Mice" *Fetal and Pediatric Pathology*, 22 Aug 2019, ISSN: 1551-3815 (Print) 1551-3823 (Online), DOI: 10.1080/15513815.2019.1651803

CLINICAL RESEARCH EXPERIENCE

- VAD+C5A, EORTC-AML, EORTC-MDS low dose ARA-C
- Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study
- The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation! Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP
- Phase III Trial of Combination Treatment with Thalidomide and Melphalan / Prednisolone for Newly Diagnosed Patients Older Than 55 Years with Multiple Myeloma who are not Candidates for High Dose Chemotherapy and Stem Cell Transplantation. Turkish Myeloma Study Group, TMSG-OOI
- A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3 Arm Parallel-Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlinid) in Combination With Melphalan and Prednisone Versus Placebo Plus

Melphalan and Prednisone in Subjects With Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older

- A randomized phase III study to compare VMP with Mel-200 followed by VRD consolidation and Lenalidomide maintenance in newly diagnosed MM patients (EMINENT study)
- A Phase III, Randomized, Open Label Trial of Lenalidomide/ Dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
- A Phase III, Randomized, Open Label Trial of Lenalidomide/ Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma
- A Phase III, Randomized, Double Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma
- A Phase III, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
- A double-blind, placebo-controlled, randomized Phase 2 study of BHQ880, an anti-Dickkopf1 (DKK1) monoclonal antibody (mAb), in patients with untreated multiple myeloma and renal insufficiency
- A Multicenter, Randomized, Double Blind, Placebo Controlled Phase 2/3 Study of LY2127399 in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma
- Randomized Controlled Phase 3 Study to Evaluate Maintenance After Retreatment With Bortezomib (VELCADE) Salvage Therapy in Patient with Multiple Myeloma in First or Second Relapse (MARS)
- A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan and Prednisone versus Bortezomib, Melphalan and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma.
- A Multicenter, single arm, open label study, with pomalidomide in combination with low dose dexametasone in subjects with refractory or relapsed and refractory multiple myeloma
- A Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Subjects with Relapsed or Refractory Multiple Myeloma
- A phase 3, Multicenter, Randomized, Open Label Study to compare the efficacy and

safety of pomalidomide, bortezomib and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma.

- A Phase 3, randomized, observer-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals herpes zoster Ge/AS01B candidate vaccine when administered intramuscularly on a two dose schedule to adult autologous haematopoietic stem cell transplant recipients.
- A randomized phase 2 trial to evaluate three daratumumab dose schedules in smoldering multiple myeloma.
- A phase 3, randomized, placebo-controlled, double-blind study of oral ixazomib maintenance therapy after initial therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplantation.
- A phase 3, Randomized, Controlled, Open-label study of velcade melphalan-prednisone (VMP) Compared to Daratumumab in combination with VMP in subjects with previously untreated multiple myeloma who are ineligible for high -dose therapy.
- A Phase II, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate The Effect of Velcade on Myeloma related Bone Disease
- A multicenter, randomized, double blind, placebo controlled, phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma
- Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t (4;14) Chromosomal Translocation
- IMF-CA204-126 – International Myeloma Foundation Study of Healthcare Resource Utilization in Relapsed and/or Refractory Multiple Myeloma: Medical Chart Review
- A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral MLN9708 Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
- A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
- Among Patients With Newly Diagnosed MM Presence of Phosphorylated Retinoblastoma and/or Cyclin A Expression is Associated with a Poor Overall Survival but can be Improved Following High Dose Therapy
- HLA-DRB1-13 and 15 are associated with response to thalidomide in patients

with Multiple Myeloma

- A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study
- A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
- A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- A phase III, Randomized, Double- Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relaps and/or Refractory Multiple Myeloma
- A Phase 3 randomized, open-label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed